Business Wire06.15.16
Thermo Fisher Scientific has signed a strategic partnership agreement with Cytonome/ST LLC to be the exclusive distributor of a new line of flow cytometry cell sorting technology that the companies will co-develop. The agreement combines Thermo Fisher’s channel reach and commercialization capabilities and Cytonome’s sorting technology expertise and heritage of disruptive innovation.
“A key goal we are helping to fulfill through this strategic partnership is to enabling scientists work as efficiently and effectively as possible,” said Valerie Bressler-Hill, vice president and general manager of Flow Cytometry at Thermo Fisher. “We are extremely impressed with the quality and remarkable ease-of-use of Cytonome’s bench-top, cell-sorter platform.”
Systems that have very short learning curves and time-saving features are critical to expedite discovery, particularly for researchers who are not familiar with flow cytometry. A key objective of the partnership is to develop easy-to-use technology designed to initiate a transformation where any scientist can readily take advantage of cell sorting in their lab and use the power of these systems to garner insights faster than ever before.
“We are very enthusiastic about this new partnership,” said Cytonome Chief Technology Officer John Sharpe. “We look forward to collaborating with Thermo Fisher to introduce innovative platforms that will result from our partnership, which we believe will change the thinking around easy-to-use bench top cell sorting.”
Thermo Fisher Scientific Inc. serves science, generating revenues of $17 billion and employing more than 50,000 employees in 50 countries. The Carlsbad, Calif., company helps customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through premier brands—Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services—we offer a combination of innovative technologies, purchasing convenience and comprehensive support.
Headquartered in Boston, Mass., Cytonome/ST is a privately held biotechnology instrument company. Cytonome develops advanced solutions in cell purification for the industrial, clinical and life science research markets.
“A key goal we are helping to fulfill through this strategic partnership is to enabling scientists work as efficiently and effectively as possible,” said Valerie Bressler-Hill, vice president and general manager of Flow Cytometry at Thermo Fisher. “We are extremely impressed with the quality and remarkable ease-of-use of Cytonome’s bench-top, cell-sorter platform.”
Systems that have very short learning curves and time-saving features are critical to expedite discovery, particularly for researchers who are not familiar with flow cytometry. A key objective of the partnership is to develop easy-to-use technology designed to initiate a transformation where any scientist can readily take advantage of cell sorting in their lab and use the power of these systems to garner insights faster than ever before.
“We are very enthusiastic about this new partnership,” said Cytonome Chief Technology Officer John Sharpe. “We look forward to collaborating with Thermo Fisher to introduce innovative platforms that will result from our partnership, which we believe will change the thinking around easy-to-use bench top cell sorting.”
Thermo Fisher Scientific Inc. serves science, generating revenues of $17 billion and employing more than 50,000 employees in 50 countries. The Carlsbad, Calif., company helps customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through premier brands—Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services—we offer a combination of innovative technologies, purchasing convenience and comprehensive support.
Headquartered in Boston, Mass., Cytonome/ST is a privately held biotechnology instrument company. Cytonome develops advanced solutions in cell purification for the industrial, clinical and life science research markets.